This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
respiratory syndrome | 1485 |
influenza virus | 1408 |
infectious diseases | 1237 |
public health | 1213 |
virus infection | 1170 |
acute respiratory | 1095 |
immune response | 1004 |
respiratory tract | 931 |
middle east | 930 |
united states | 882 |
east respiratory | 823 |
immune responses | 805 |
cord uid | 786 |
doc id | 786 |
syndrome coronavirus | 756 |
risk factors | 726 |
infectious disease | 702 |
zika virus | 700 |
respiratory syncytial | 682 |
respiratory viruses | 654 |
amino acid | 651 |
syncytial virus | 651 |
ebola virus | 620 |
type i | 611 |
saudi arabia | 610 |
gene expression | 606 |
viral infection | 560 |
innate immune | 544 |
cell lines | 541 |
porcine epidemic | 540 |
severe acute | 538 |
bone marrow | 538 |
viral infections | 537 |
viral rna | 508 |
immune system | 504 |
infected cells | 496 |
rna viruses | 482 |
epidemic diarrhea | 481 |
intensive care | 480 |
systematic review | 475 |
cell culture | 466 |
diarrhea virus | 458 |
performed using | 451 |
avian influenza | 444 |
nucleic acid | 442 |
present study | 442 |
statistically significant | 427 |
epithelial cells | 419 |
viral replication | 415 |
cell line | 414 |
significantly higher | 410 |
dendritic cells | 408 |
influenza viruses | 407 |
stem cell | 405 |
previous studies | 402 |
respiratory infections | 392 |
clinical signs | 391 |
world health | 381 |
previously described | 371 |
health care | 371 |
mg kg | 370 |
amino acids | 369 |
lower respiratory | 367 |
infection control | 366 |
clinical trials | 361 |
cov infection | 361 |
hand hygiene | 357 |
significant differences | 355 |
infectious bronchitis | 353 |
virus replication | 347 |
health organization | 346 |
weight loss | 344 |
two groups | 342 |
antiviral activity | 336 |
control group | 333 |
respiratory distress | 327 |
chain reaction | 324 |
minimally invasive | 324 |
stem cells | 324 |
critically ill | 323 |
design method | 319 |
mg ml | 319 |
significant difference | 317 |
polymerase chain | 315 |
viral load | 313 |
transplant recipients | 312 |
tract infections | 306 |
room temperature | 302 |
time pcr | 302 |
authors declare | 296 |
acquired pneumonia | 296 |
vero cells | 294 |
hospital stay | 293 |
may also | 291 |
disease control | 290 |
escherichia coli | 290 |
hiv aids | 286 |
care unit | 286 |
breast cancer | 279 |
host cell | 275 |
flow cytometry | 274 |
staphylococcus aureus | 274 |
years old | 273 |
important role | 272 |
immunodeficiency virus | 271 |
spinal cord | 270 |
innate immunity | 267 |
bariatric surgery | 266 |
bronchitis virus | 262 |
respiratory disease | 261 |
distress syndrome | 255 |
neutralizing antibodies | 255 |
young children | 254 |
reverse transcription | 253 |
hong kong | 251 |
mouse model | 251 |
virus disease | 250 |
virus type | 249 |
immune cells | 247 |
disease virus | 247 |
virus infections | 246 |
lymph nodes | 246 |
laparoscopic surgery | 245 |
respiratory viral | 243 |
increased risk | 242 |
rna virus | 242 |
time points | 240 |
upper respiratory | 239 |
least one | 238 |
lymph node | 235 |
monoclonal antibody | 233 |
phylogenetic analysis | 233 |
results showed | 232 |
one patient | 232 |
pandemic influenza | 230 |
spike protein | 230 |
south korea | 229 |
days post | 229 |
dengue virus | 228 |
closely related | 228 |
operative time | 227 |
serum samples | 227 |
genetic diversity | 226 |
cohort study | 223 |
vaccine development | 223 |
influenza infection | 221 |
i ifn | 221 |
influenza vaccine | 220 |
protein expression | 220 |
current study | 219 |
pediatric patients | 219 |
laparoscopic approach | 218 |
cancer cells | 218 |
cell death | 215 |
like receptor | 215 |
human metapneumovirus | 214 |
supplementary material | 214 |
risk factor | 214 |
chronic hepatitis | 214 |
gastric cancer | 213 |
porcine reproductive | 213 |
fever virus | 212 |
syndrome virus | 211 |
signaling pathway | 210 |
mechanical ventilation | 209 |
nervous system | 209 |
viral proteins | 209 |
determine whether | 208 |
ill patients | 207 |
tract infection | 206 |
human immunodeficiency | 205 |
peripheral blood | 205 |
rna polymerase | 204 |
cell surface | 204 |
significantly lower | 203 |
case report | 203 |
zikv infection | 203 |
thermo fisher | 202 |
viral genome | 201 |
described previously | 200 |
hbv dna | 200 |
cell transplantation | 199 |
animal models | 198 |
gastric bypass | 198 |
global health | 197 |
respiratory virus | 197 |
supplementary table | 195 |
stranded rna | 194 |
pcr assay | 193 |
ng ml | 193 |
i interferon | 193 |
patients undergoing | 192 |
abdominal pain | 192 |
highly pathogenic | 192 |
host cells | 191 |
respiratory failure | 191 |
even though | 191 |
infected mice | 191 |
sleeve gastrectomy | 189 |
climate change | 188 |
inflammatory response | 188 |
widely used | 188 |
clinical practice | 188 |
hematopoietic stem | 188 |
well plates | 187 |
monoclonal antibodies | 187 |
hemorrhagic fever | 187 |
cell responses | 186 |
mg dl | 186 |
social media | 186 |
recent years | 186 |
high risk | 185 |
western blot | 185 |
mortality rate | 184 |
previously reported | 184 |
emerging infectious | 184 |
encephalitis virus | 184 |
statistical analysis | 182 |
healthcare workers | 182 |
west nile | 181 |
chikungunya virus | 181 |
herpes simplex | 180 |
sialic acid | 180 |
commonly used | 179 |
central nervous | 179 |
vaccinia virus | 179 |
oxidative stress | 178 |
age groups | 178 |
introduction background | 178 |
previous study | 178 |
parainfluenza virus | 178 |
mean age | 178 |
blood samples | 177 |
antiviral therapy | 176 |
mammalian cells | 176 |
mesenchymal stem | 176 |
respiratory illness | 176 |
three times | 176 |
fisher scientific | 176 |
growth factor | 176 |
plasmodium falciparum | 175 |
codon usage | 175 |
body weight | 175 |
nucleic acids | 175 |
wide range | 174 |
inflammatory cytokines | 174 |
clinical trial | 174 |
one health | 173 |
data collection | 173 |
emergency department | 173 |
old male | 172 |
bacterial infections | 172 |
control measures | 171 |
two different | 171 |
blood loss | 171 |
negative control | 171 |
vesicular stomatitis | 170 |
retrospective study | 170 |
dependent manner | 169 |
data analysis | 168 |
old female | 168 |
analyzed using | 166 |
mental health | 166 |
dromedary camels | 166 |
statistical significance | 166 |
clinical outcomes | 165 |
informed consent | 165 |
side effects | 165 |
standard deviation | 164 |
like particles | 164 |
isothermal amplification | 164 |
class i | 163 |
respiratory symptoms | 163 |
stomatitis virus | 163 |
also found | 162 |
respiratory infection | 162 |
expression levels | 162 |
also known | 162 |
high levels | 161 |
age group | 161 |
virus detection | 161 |
nile virus | 161 |
year old | 161 |
simplex virus | 161 |
coronavirus infection | 160 |
large number | 160 |
time rt | 160 |
electron microscopy | 159 |
prospective study | 158 |
associated pneumonia | 158 |
postoperative complications | 158 |
mass spectrometry | 158 |
recent study | 157 |
case series | 157 |
cell proliferation | 157 |
necrosis factor | 157 |
another study | 157 |
antibody responses | 156 |
rectal cancer | 156 |
mortality rates | 155 |
adverse events | 155 |
cancer patients | 155 |
results suggest | 155 |
median age | 155 |
study period | 154 |
cell types | 154 |
transmissible gastroenteritis | 154 |
ct scan | 153 |
significantly increased | 153 |
hernia repair | 153 |
seasonal influenza | 153 |
controlled trial | 152 |
antibody response | 151 |
specific antibody | 151 |
host immune | 151 |
disease severity | 150 |
several studies | 150 |
total number | 150 |
reactive oxygen | 149 |
yellow fever | 149 |
membrane fusion | 149 |
patients underwent | 149 |
binding domain | 148 |
states background | 148 |
infected patients | 148 |
respiratory pathogens | 148 |
adaptive immune | 148 |
human papillomavirus | 148 |
mrna expression | 147 |
immune deficiency | 147 |
structural proteins | 147 |
results indicate | 146 |
protein kinase | 146 |
mhc class | 146 |
two patients | 146 |
influenza pandemic | 145 |
logistic regression | 145 |
fecal samples | 145 |
signaling pathways | 144 |
west africa | 144 |
canine parvovirus | 143 |
cd cd | 143 |
oxygen species | 143 |
day post | 142 |
significantly reduced | 142 |
hepatocellular carcinoma | 142 |
binding site | 142 |
virus particles | 142 |
kidney injury | 142 |
tumor necrosis | 141 |
recent studies | 140 |
antiviral response | 140 |
goat anti | 139 |
copies ml | 139 |
adult patients | 139 |
western blotting | 138 |
bovine serum | 138 |
class ii | 138 |
acute kidney | 138 |
i i | 137 |
sample size | 137 |
drug resistance | 137 |
significant increase | 136 |
natural products | 135 |
bacterial infection | 135 |
taken together | 135 |
first time | 135 |
time point | 135 |
enveloped viruses | 135 |
analysis showed | 135 |
survival rate | 135 |
life cycle | 134 |
cells infected | 134 |
clinical presentation | 134 |
significantly different | 134 |
liver failure | 133 |
dna viruses | 133 |
may lead | 132 |
human health | 132 |
bile duct | 132 |
solid organ | 132 |
wound healing | 132 |
gold nanoparticles | 132 |
commercially available | 132 |
defective interfering | 132 |
human coronavirus | 131 |
nk cells | 131 |
tumor cells | 131 |
clinical features | 131 |
hospitalized patients | 131 |
virus strains | 131 |
years ago | 131 |
competing interests | 130 |
data suggest | 130 |
viral pathogens | 130 |
patients treated | 129 |
total rna | 129 |
multiplex pcr | 129 |
overall survival | 129 |
among children | 129 |
laparoscopic cholecystectomy | 129 |
patients received | 128 |
bat species | 128 |
specific antibodies | 128 |
phylogenetic tree | 128 |
way anova | 127 |
pulmonary disease | 127 |
binding protein | 127 |
protein levels | 127 |
cell cycle | 127 |
blood cell | 127 |
one study | 127 |
positive samples | 127 |
icu admission | 127 |
medical center | 126 |
filmarray rp | 126 |
sierra leone | 126 |
endothelial cells | 126 |
lung injury | 126 |
plasma membrane | 126 |
neutralizing antibody | 125 |
barr virus | 125 |
receptor binding | 125 |
mouse models | 125 |
long term | 125 |
animal health | 124 |
red blood | 124 |
samples collected | 124 |
combination therapy | 124 |
viral respiratory | 124 |
developing countries | 124 |
case study | 123 |
health services | 123 |
fusion protein | 123 |
rapid detection | 123 |
like receptors | 123 |
among patients | 123 |
lung disease | 122 |
human security | 122 |
creative commons | 122 |
generation sequencing | 122 |
swine fever | 122 |
tissue culture | 122 |
viral protein | 122 |
colorectal cancer | 122 |
positive patients | 122 |
severe respiratory | 122 |
health system | 121 |
inhibitory activity | 121 |
mediated isothermal | 121 |
liver transplantation | 121 |
future studies | 121 |
complete genome | 121 |
operation time | 121 |
diagnostic tests | 120 |
real time | 120 |
mouth disease | 120 |
additional file | 120 |
incubation period | 119 |
disease outbreaks | 119 |
capsid protein | 118 |
study showed | 118 |
core protein | 118 |
viral particles | 118 |
septic shock | 118 |
viral dna | 118 |
patients without | 118 |
phase i | 118 |
different types | 117 |
study design | 117 |
data set | 117 |
transcription factor | 117 |
dub activity | 117 |
virus vaccine | 117 |
robotic surgery | 116 |
dendritic cell | 116 |
postoperative day | 116 |
influenza vaccination | 116 |
patients admitted | 115 |
literature review | 115 |
rna synthesis | 115 |
wind speed | 115 |
factors associated | 115 |
viral genomes | 114 |
nitric oxide | 114 |
mass gatherings | 114 |
ns protein | 114 |
clinical symptoms | 114 |
positive control | 114 |
cellular immune | 114 |
cell cultures | 114 |
viral titers | 113 |
japanese encephalitis | 113 |
similar results | 113 |
patients receiving | 113 |
food safety | 113 |
clinical manifestations | 113 |
newcastle disease | 113 |
also used | 113 |
streptococcus pneumoniae | 113 |
critical care | 113 |
also observed | 113 |
clinical samples | 113 |
infectious virus | 112 |
chart review | 112 |
positive cells | 112 |
treated mice | 112 |
supplementary information | 112 |
antibiotic use | 112 |
cell transplant | 111 |
binding affinity | 111 |
sickle cell | 111 |
genome sequence | 111 |
protein synthesis | 110 |
randomized controlled | 110 |
antiviral treatment | 110 |
older adults | 110 |
reverse transcriptase | 110 |
tested positive | 110 |
pcr assays | 109 |
small bowel | 109 |
independent experiments | 109 |
nucleocapsid protein | 108 |
cell activation | 108 |
inclusion criteria | 108 |
blood culture | 108 |
hela cells | 108 |
gastrointestinal tract | 107 |
prostate cancer | 107 |
results show | 107 |
fatty acid | 107 |
new zealand | 106 |
hiatal hernia | 106 |
hospitalized children | 106 |
gold standard | 106 |
vaccine candidates | 106 |
molecular characterization | 106 |
three patients | 105 |
pathogenic avian | 105 |
children aged | 105 |
severe disease | 105 |
urinary tract | 105 |
mrna levels | 105 |
computed tomography | 105 |
gastroenteritis virus | 105 |
blood cells | 105 |
clinical characteristics | 105 |
within days | 104 |
per day | 104 |
small intestine | 104 |
ethics committee | 104 |
small molecule | 104 |
cystic fibrosis | 104 |
crystal structure | 104 |
natural killer | 104 |
disease transmission | 104 |
human respiratory | 103 |
three different | 103 |
viral entry | 103 |
sequence analysis | 103 |
pregnant women | 103 |
cancer therapy | 103 |
low levels | 102 |
critical role | 102 |
hospital mortality | 102 |
cerebral malaria | 102 |
protein interactions | 102 |
highly conserved | 102 |
pseudomonas aeruginosa | 102 |
calculated using | 102 |
also reported | 102 |
antibody titers | 102 |
antimicrobial resistance | 101 |
adaptive immunity | 101 |
type ii | 101 |
th cells | 101 |
high mortality | 100 |
whole blood | 100 |
higher risk | 100 |
cell viability | 100 |
bronchoalveolar lavage | 100 |
endoplasmic reticulum | 100 |
replacement therapy | 100 |
reproduction number | 100 |
high prevalence | 100 |
antiviral agents | 100 |
wind tunnel | 99 |
graphpad prism | 99 |
medical records | 99 |
hepg cells | 99 |
blood cultures | 99 |
human influenza | 99 |
cord injury | 99 |
antibiotic treatment | 99 |
high level | 99 |
retrospective analysis | 99 |
infectious agents | 99 |
viral loads | 99 |
african swine | 99 |
human rhinovirus | 99 |
organ transplant | 98 |
infected individuals | 98 |
vaccine candidate | 98 |
invasive surgery | 98 |
cell growth | 98 |
respiratory diseases | 98 |
one year | 98 |
measured using | 98 |
higher levels | 98 |
infected animals | 98 |
confirmed cases | 98 |
ifn signaling | 98 |
per year | 97 |
treated group | 97 |
acute phase | 97 |
may help | 97 |
essential oils | 97 |
findings suggest | 97 |
treg cells | 97 |
determined using | 97 |
analysis revealed | 97 |
virus entry | 97 |
big data | 97 |
live attenuated | 97 |
molecular mechanisms | 96 |
nipah virus | 96 |
buffered saline | 96 |
pilot study | 96 |
host factors | 96 |
host range | 96 |
platelet count | 96 |
south africa | 96 |
may provide | 95 |
underwent laparoscopic | 95 |
virus rna | 95 |
tcid ml | 95 |
key role | 95 |
virus strain | 94 |
active site | 94 |
confidence interval | 94 |
human rights | 94 |
first step | 94 |
infection prevention | 94 |
tfr cells | 94 |
renal transplant | 93 |
gene therapy | 93 |
pet substrate | 93 |
fetal bovine | 93 |
bacterial pathogens | 93 |
nucleotide sequences | 93 |
colon cancer | 93 |
diabetes mellitus | 93 |
mers coronavirus | 92 |
springer nature | 92 |
human disease | 92 |
decision making | 92 |
four patients | 92 |
porcine deltacoronavirus | 92 |
host species | 92 |
may contribute | 92 |
antiviral drugs | 92 |
open reading | 92 |
hcv core | 92 |
united kingdom | 92 |
jurisdictional claims | 92 |
remains neutral | 92 |
nature remains | 91 |
dna polymerase | 91 |
north america | 91 |
better understand | 91 |
institutional affiliations | 91 |
care units | 91 |
abdominal wall | 91 |
cell epitopes | 91 |
rabies virus | 91 |
human cells | 91 |
culture medium | 91 |
published maps | 91 |
linked immunosorbent | 91 |
income countries | 91 |
new york | 91 |
retrospective chart | 91 |
immunocompromised patients | 91 |
significant reduction | 91 |
inhibitory effect | 90 |
cell receptor | 90 |
clinical data | 90 |
copy number | 90 |
detection limit | 90 |
university hospital | 90 |
disease progression | 90 |
cell membrane | 90 |
may result | 90 |
igg antibodies | 90 |
antigen presentation | 90 |
national institute | 90 |
significantly associated | 90 |
regression analysis | 90 |
molecular weight | 90 |
animal model | 89 |
porcine circovirus | 89 |
pcr products | 89 |
pedv strains | 89 |
pg ml | 89 |
adverse effects | 89 |
detection rate | 89 |
mononuclear cells | 89 |
viral diseases | 89 |
lung cancer | 89 |
genbank accession | 89 |
highly infectious | 89 |
body mass | 89 |
antimicrobial activity | 88 |
strand rna | 88 |
term outcomes | 88 |
fusion proteins | 88 |
health security | 88 |
influenza vaccines | 88 |
mm nacl | 88 |
mm tris | 88 |
life technologies | 88 |
viral shedding | 88 |
prrsv nsp | 88 |
also showed | 88 |
differential diagnosis | 87 |
control study | 87 |
fruit bats | 87 |
ge healthcare | 87 |
surveillance system | 87 |
virus transmission | 87 |
communicable diseases | 87 |
drug discovery | 87 |
previous reports | 87 |
better understanding | 87 |
hcv infection | 87 |
significantly decreased | 87 |
helicobacter pylori | 87 |
chronic obstructive | 87 |
post infection | 87 |
cytokine production | 87 |
target dna | 87 |
liver disease | 87 |
pedv infection | 87 |
stromal cells | 86 |
cmv infection | 86 |
blood flow | 86 |
disaster management | 86 |
antiviral activities | 86 |
gel electrophoresis | 86 |
well known | 86 |
acute lung | 86 |
lung transplant | 86 |
tissue damage | 86 |
sars coronavirus | 86 |
pr virus | 86 |
five patients | 86 |
dependent rna | 86 |
primary immunodeficiency | 86 |
bovine viral | 86 |
cell lysates | 86 |
one case | 85 |
general surgery | 85 |
reading frame | 85 |
human population | 85 |
rna replication | 85 |
disease surveillance | 85 |
small molecules | 85 |
dna vaccine | 85 |
bovine respiratory | 85 |
fungal infections | 85 |
next generation | 85 |
ex vivo | 85 |
ebola outbreak | 85 |
cell entry | 85 |
cell disease | 84 |
immunosorbent assay | 84 |
learning curve | 84 |
human adenovirus | 84 |
general population | 84 |
assessed using | 84 |
cd cells | 84 |
oral health | 84 |
inguinal hernia | 84 |
immune function | 84 |
blood pressure | 84 |
gene sequences | 84 |
antibiotic resistance | 84 |
transplant patients | 84 |
study demonstrated | 83 |
treatment group | 83 |
health status | 83 |
primary care | 83 |
transcription factors | 83 |
rabbit anti | 83 |
ccl mrna | 83 |
protective immunity | 83 |
observational study | 83 |
positive results | 83 |
tumor growth | 83 |
molecular epidemiology | 83 |
study group | 82 |
survival rates | 82 |
environmental factors | 82 |
research resources | 82 |
sense rna | 82 |
optimal control | 82 |
data sets | 82 |
last years | 82 |
autoimmune diseases | 82 |
negative controls | 82 |
control strategies | 82 |
wild birds | 82 |
highly sensitive | 82 |
avian infectious | 82 |
nucleotide sequence | 82 |
well plate | 81 |
retrospective review | 81 |
like illness | 81 |
many studies | 81 |
nk cell | 81 |
gut microbiota | 81 |
acid sequence | 81 |
clinical studies | 81 |
medicinal plants | 81 |
statistical analyses | 81 |
clostridium difficile | 81 |
cells expressing | 81 |
specific igg | 81 |
quantitative pcr | 81 |
early detection | 81 |
rna interference | 81 |
naturally occurring | 81 |
carbon emissions | 81 |
specific igy | 81 |
severe influenza | 80 |
kidney disease | 80 |
study found | 80 |
three groups | 80 |
sequence alignment | 80 |
egg yolk | 80 |
hbv infection | 80 |
indocyanine green | 80 |
indirect elisa | 80 |
mouse anti | 80 |
time series | 80 |
human infection | 80 |
contact tracing | 80 |
retrospective cohort | 79 |
protective effect | 79 |
target cells | 79 |
dipeptidyl peptidase | 79 |
patient care | 79 |
cancer stem | 79 |
treatment groups | 79 |
may occur | 79 |
virus genome | 79 |
borne encephalitis | 79 |
genome sequences | 79 |
guangdong province | 79 |
anastomotic leak | 79 |
viral etiology | 79 |
first report | 79 |
measles virus | 79 |
human parainfluenza | 79 |
early stages | 79 |
coronavirus spike | 79 |
early stage | 78 |
cases reported | 78 |
correlation coefficient | 78 |
obstructive pulmonary | 78 |
three days | 78 |
national health | 78 |
white blood | 78 |
young adults | 78 |
surg endosc | 78 |
physical activity | 78 |
ic values | 78 |
ms ms | 78 |
genome sequencing | 78 |
marburg virus | 78 |
two cases | 78 |
structural basis | 78 |
secondary antibody | 78 |
reactive protein | 78 |
mass index | 78 |
like virus | 77 |
ifn production | 77 |
small number | 77 |
case fatality | 77 |
disease outbreak | 77 |
included patients | 77 |
health systems | 77 |
causative agent | 77 |
may cause | 77 |
southern china | 77 |
host defense | 77 |
like particle | 77 |
rift valley | 77 |
southeast asia | 77 |
economic losses | 77 |
risk assessment | 77 |
three independent | 76 |
national institutes | 76 |
fatality rate | 76 |
eucalyptus camaldulensis | 76 |
different time | 76 |
inflammatory responses | 76 |
open surgery | 76 |
among different | 76 |
culture supernatants | 76 |
may play | 76 |
phase ii | 76 |
kawasaki disease | 76 |
essential oil | 76 |
study also | 75 |
online version | 75 |
hematopoietic cell | 75 |
severe dengue | 75 |
stranded dna | 75 |
nested pcr | 75 |
rsv infection | 75 |
valley fever | 75 |
cell count | 75 |
gene delivery | 75 |
much higher | 75 |
remains unclear | 75 |
human airway | 75 |
terminal domain | 75 |
nonstructural protein | 75 |
studies using | 75 |
respiratory coronavirus | 75 |
positive selection | 75 |
detection methods | 75 |
dengue fever | 75 |
review board | 75 |
multiple sclerosis | 75 |
intravenous immunoglobulin | 75 |
infection may | 75 |
test results | 75 |
two independent | 75 |
based vaccine | 75 |
supportive care | 75 |
host response | 74 |
data collected | 74 |
moving objects | 74 |
infectious peritonitis | 74 |
mycobacterium tuberculosis | 74 |
vaccine efficacy | 74 |
com scientificreports | 74 |
cho cells | 74 |
multiple myeloma | 74 |
global burden | 74 |
toxoplasma gondii | 74 |
membrane proteins | 74 |
observational studies | 74 |
indoor environment | 74 |
membrane protein | 74 |
dna replication | 74 |
cell type | 74 |
less likely | 74 |
cov spike | 74 |
per well | 74 |
acid sequences | 74 |
feline infectious | 74 |
leading cause | 73 |
exome sequencing | 73 |
thermo scientific | 73 |
pedv strain | 73 |
disease burden | 73 |
surgical treatment | 73 |
organ failure | 73 |
acute lymphoblastic | 73 |
diffuse alveolar | 73 |
heart disease | 73 |
exact test | 73 |
sample collection | 73 |
mhc i | 73 |
nosocomial infections | 73 |
chitosan nanoparticles | 73 |
phylogenetic trees | 73 |
resistant staphylococcus | 73 |
machine learning | 73 |
porcine respiratory | 72 |
mice infected | 72 |
institutional review | 72 |
drug delivery | 72 |
currently available | 72 |
clinical disease | 72 |
experimental data | 72 |
renal failure | 72 |
lymphoblastic leukemia | 72 |
direct contact | 72 |
relatively high | 72 |
early diagnosis | 72 |
high sensitivity | 72 |
pattern recognition | 72 |
hcv ns | 72 |
supporting information | 72 |
vaccinated animals | 72 |
bowel obstruction | 71 |
disease prevention | 71 |
crispr cas | 71 |
drug administration | 71 |
proinflammatory cytokines | 71 |
genomic dna | 71 |
node dissection | 71 |
physical examination | 71 |
hospital admission | 71 |
growth factors | 71 |
broad spectrum | 71 |
wild type | 71 |
surgical procedure | 71 |
au mos | 71 |
wide variety | 71 |
sanger sequencing | 71 |
democratic republic | 71 |
old woman | 71 |
protective equipment | 71 |
results indicated | 71 |
liver function | 71 |
smooth muscle | 71 |
differentially expressed | 71 |
lateral flow | 71 |
mass gathering | 71 |
future research | 71 |
molecular detection | 70 |
viral disease | 70 |
rheumatoid arthritis | 70 |
spectrum antiviral | 70 |
control groups | 70 |
antibiotic therapy | 70 |
clinical course | 70 |
temporal networks | 70 |
antiviral immunity | 70 |
animal care | 70 |
novel coronavirus | 70 |
study aimed | 70 |
genes involved | 70 |
nuclear factor | 70 |
community detection | 70 |
data indicate | 70 |
accession number | 70 |
plaque assay | 70 |
will also | 70 |
interfering particles | 70 |
medical students | 70 |
west african | 70 |
lysis buffer | 70 |
inflammatory cytokine | 70 |
analysis using | 70 |
viral diarrhea | 70 |
accession numbers | 70 |
cells treated | 69 |
rna binding | 69 |
quality control | 69 |
corticosteroid therapy | 69 |
healthy controls | 69 |
bearing mice | 69 |
antibody levels | 69 |
case reports | 69 |
medical history | 69 |
genetic variation | 69 |
health emergency | 69 |
genetic analysis | 69 |
human populations | 69 |
thrombocytopenic purpura | 69 |
mdck cells | 69 |
experimental infection | 69 |
quality improvement | 69 |
zoonotic diseases | 69 |
two weeks | 69 |
clinical outcome | 69 |
recognition receptors | 69 |
virus production | 69 |
standard curve | 69 |
high dose | 69 |
average age | 69 |
recombinant protein | 69 |
fl fl | 69 |
first case | 69 |
gut microbiome | 69 |
virus titers | 69 |
diarrhoea virus | 69 |
cumulative incidence | 68 |
drug development | 68 |
protective efficacy | 68 |
deep sequencing | 68 |
nasal swabs | 68 |
influenza season | 68 |
antiviral effect | 68 |
hepatitis virus | 68 |
vlp vaccines | 68 |
whole genome | 68 |
will help | 68 |
reading frames | 68 |
major histocompatibility | 68 |
matrix protein | 67 |
ifnar fl | 67 |
applied biosystems | 67 |
binding sites | 67 |
relatively low | 67 |
human transmission | 67 |
reverse genetics | 67 |
treatment options | 67 |
vaccine strains | 67 |
time step | 67 |
prospective cohort | 67 |
blot analysis | 67 |
time period | 67 |
patients may | 67 |
patient presented | 67 |
spike glycoprotein | 67 |
master mix | 67 |
studies showed | 66 |
conducted using | 66 |
viral fitness | 66 |
air pollution | 66 |
multivariate analysis | 66 |
diagnostic methods | 66 |
see table | 66 |
severe pneumonia | 66 |
ec cells | 66 |
fold higher | 66 |
symptom onset | 66 |
mice treated | 66 |
dna vaccines | 66 |
induced apoptosis | 66 |
white matter | 66 |
two years | 66 |
laparoscopic sleeve | 66 |
cell density | 66 |
mechanically ventilated | 66 |
phage display | 66 |
agarose gel | 66 |
species transmission | 66 |
structural protein | 66 |
type diabetes | 66 |
final concentration | 66 |
free survival | 66 |
prone positioning | 66 |
virus isolation | 65 |
rhesus macaques | 65 |
serum albumin | 65 |
purified using | 65 |
patient underwent | 65 |
cancer cell | 65 |
will need | 65 |
secondary bacterial | 65 |
virus shedding | 65 |
viral titer | 65 |
day mortality | 65 |
linear regression | 65 |
health emergencies | 65 |
neutralizing activity | 65 |
vaccine strain | 65 |
study population | 65 |
antibody production | 65 |
extracted using | 65 |
factor receptor | 65 |
au nanolayer | 65 |
health authorities | 65 |
transmission dynamics | 65 |
surface area | 65 |
recent advances | 65 |
also identified | 65 |
commons license | 65 |
infection rate | 65 |
evaluated using | 65 |
results obtained | 64 |
protein interaction | 64 |
common cold | 64 |
neutralization assay | 64 |
based vaccines | 64 |
viral pneumonia | 64 |
body temperature | 64 |
log copies | 64 |
antiviral drug | 64 |
bacterial pneumonia | 64 |
two types | 64 |
surgical site | 64 |
blood transfusion | 64 |
pedestrian level | 64 |
days later | 64 |
serially diluted | 64 |
acid amplification | 64 |
time reverse | 64 |
immune cell | 64 |
fatty acids | 64 |
surgical procedures | 64 |
swine influenza | 64 |
lung tissue | 64 |
alveolar macrophages | 64 |
infection rates | 64 |
population density | 64 |
following infection | 63 |
blood mononuclear | 63 |
clinical impact | 63 |
ellagic acid | 63 |
acute infection | 63 |
vast majority | 63 |
past years | 63 |
secondary structure | 63 |
many countries | 63 |
epidemic diarrhoea | 63 |
cmv reactivation | 63 |
generated using | 63 |
chronic kidney | 63 |
associated infections | 63 |
continuous variables | 63 |
colorectal surgery | 63 |
inflammatory bowel | 63 |
mesenchymal stromal | 63 |
one hundred | 63 |
feline coronavirus | 63 |
least two | 63 |
previously published | 63 |
infected controls | 63 |
broad range | 63 |
close contact | 63 |
salmonella typhimurium | 63 |
mediated antiviral | 63 |
phase iii | 63 |
million people | 63 |
cells via | 63 |
kindly provided | 63 |
san diego | 63 |
histocompatibility complex | 63 |
conjugated goat | 63 |
cells ml | 62 |
long time | 62 |
abdominal cavity | 62 |
basic reproduction | 62 |
four different | 62 |
patient outcomes | 62 |
health effects | 62 |
social networks | 62 |
human cd | 62 |
pancreatic cancer | 62 |
patients aged | 62 |
post hoc | 62 |
old man | 62 |
binding proteins | 62 |
fold increase | 62 |
error bars | 62 |
surgical intervention | 62 |
common cause | 62 |
risk perception | 62 |
increased mortality | 62 |
cleavage site | 62 |
horseradish peroxidase | 62 |
mos au | 62 |
organ dysfunction | 62 |
cerebrospinal fluid | 62 |
allogeneic hematopoietic | 62 |
well tolerated | 61 |
two major | 61 |
pharmacy practice | 61 |
regression model | 61 |
mucosal immune | 61 |
therapeutic strategies | 61 |
care workers | 61 |
considered statistically | 61 |
diagnostic test | 61 |
south america | 61 |
asthma exacerbations | 61 |
expression level | 61 |
cell populations | 61 |
myeloid cells | 61 |
phosphate dehydrogenase | 61 |
cov clpro | 61 |
conventional laparoscopic | 61 |
reported cases | 61 |
fold change | 61 |
bioterrorism agents | 61 |
open access | 61 |
solid tumors | 61 |
evidence suggests | 61 |
negative bacteria | 61 |
tfr treg | 61 |
recombinant proteins | 61 |
lung transplantation | 61 |
single cell | 61 |
new insights | 61 |
cancer treatment | 61 |
liver transplant | 61 |
essential role | 61 |
tissue samples | 61 |
postoperative pain | 61 |
anastomotic leakage | 61 |
crude extract | 61 |
significantly improved | 61 |
specific cd | 61 |
alexa fluor | 61 |
newborn piglets | 60 |
family members | 60 |
vaccination strategies | 60 |
pathogenic bacteria | 60 |
salt bridge | 60 |
per cent | 60 |
product quality | 60 |
antiviral responses | 60 |
sore throat | 60 |
vaccination coverage | 60 |
working group | 60 |
cells transfected | 60 |
different cell | 60 |
signal transduction | 60 |
bovine herpesvirus | 60 |
methods used | 60 |
cell response | 60 |
tgev prcv | 60 |
global public | 60 |
personal protective | 60 |
hiv infection | 60 |
presenting cells | 60 |
vaccine effectiveness | 60 |
standard deviations | 60 |
positively charged | 60 |
ibv strains | 60 |
higher mortality | 60 |
viral membrane | 60 |
antibody titres | 60 |
infections among | 60 |
two days | 60 |
categorical variables | 60 |
regulatory factor | 60 |
pediatric oncology | 60 |
dis doi | 60 |
chronic diseases | 60 |
clinical significance | 60 |
antimicrobial peptides | 60 |
rna copies | 60 |
virus evolution | 60 |
transcription polymerase | 59 |
virus ns | 59 |
controlled trials | 59 |
long noncoding | 59 |
mediated immunity | 59 |
first reported | 59 |
conversion rate | 59 |
technological opportunities | 59 |
study conducted | 59 |
patients infected | 59 |
capsid proteins | 59 |
acute care | 59 |
patient developed | 59 |
diagnostic testing | 59 |
often used | 59 |
secondary antibodies | 59 |
vp gene | 59 |
infection risk | 59 |
occupant health | 59 |
clinically relevant | 59 |
primary outcome | 59 |
infection among | 59 |
likely due | 59 |
cardiac surgery | 59 |
interferon signaling | 59 |
alveolar hemorrhage | 59 |
homologous recombination | 59 |
cov ma | 59 |
peer review | 59 |
membrane oxygenation | 59 |
combined immunodeficiency | 59 |
molecular biology | 59 |
sequence data | 59 |
primary antibodies | 59 |
odds ratio | 58 |
neighborhood environment | 58 |
surveillance data | 58 |
transgenic mice | 58 |
preliminary results | 58 |
respiratory pathogen | 58 |
potential role | 58 |
hek cells | 58 |
studies reported | 58 |
progenitor cells | 58 |
practice guidelines | 58 |
reaction mixture | 58 |
rna sequencing | 58 |
usage bias | 58 |
endemic equilibrium | 58 |
steady state | 58 |
significant decrease | 58 |
expression system | 58 |
prolonged exercise | 58 |
aged years | 58 |
human pathogens | 58 |
median time | 58 |
protein production | 58 |
infected group | 58 |
animal species | 58 |
envelope protein | 58 |
gestational age | 58 |
also included | 58 |
santa cruz | 58 |
one week | 58 |
go terms | 58 |
also demonstrated | 58 |
heart failure | 58 |
united nations | 58 |
newly discovered | 58 |
cell counts | 58 |
high rate | 58 |
intestinal tract | 58 |
respiratory panel | 58 |
human serum | 58 |
cov replication | 58 |
pd deficiency | 57 |
analysis based | 57 |
domestic cats | 57 |
considered significant | 57 |
dairy cattle | 57 |
infected cell | 57 |
immune evasion | 57 |
pcr amplification | 57 |
high incidence | 57 |
envelope glycoprotein | 57 |
extracorporeal membrane | 57 |
microbial communities | 57 |
innate antiviral | 57 |
healthcare services | 57 |
transfected cells | 57 |
oral administration | 57 |
simultaneous detection | 57 |
renal function | 57 |
interferon regulatory | 57 |
pcr using | 57 |
natural selection | 57 |
experimentally infected | 57 |
ics ii | 57 |
virus core | 57 |
na activity | 57 |
vp protein | 57 |
boundary conditions | 57 |
kg day | 57 |
liver cirrhosis | 57 |
cell differentiation | 57 |
host interactions | 57 |
nonstructural proteins | 57 |
brain injury | 57 |
take place | 56 |
associated protein | 56 |
dna virus | 56 |
prospective studies | 56 |
cirrhotic patients | 56 |
skeletal muscle | 56 |
airway epithelial | 56 |
using different | 56 |
airway epithelium | 56 |
humoral immune | 56 |
cells using | 56 |
transfection efficiency | 56 |
leukemia virus | 56 |
clinical diagnosis | 56 |
kidney transplant | 56 |
detected using | 56 |
higher incidence | 56 |
infectious complications | 56 |
genetic characterization | 56 |
newborn screening | 56 |
patients presenting | 56 |
clinical use | 56 |
epidemiological data | 56 |
data obtained | 56 |
commons attribution | 56 |
patient population | 56 |
two decades | 56 |
dsrna viruses | 56 |
iu ml | 56 |
african countries | 56 |
results suggested | 56 |
disseminated intravascular | 56 |
nuclear translocation | 56 |
like viruses | 56 |
whole exome | 56 |
washed three | 56 |
saharan africa | 56 |
icu patients | 56 |
patient safety | 56 |
cells well | 56 |
iav infection | 56 |
deep learning | 56 |
weight gain | 56 |
wind environment | 56 |
like syndrome | 56 |
surgical technique | 56 |
mv vac | 56 |
surgical resection | 56 |
specific pathogen | 56 |
clinical management | 56 |
epidemic spreading | 56 |
case definition | 55 |
health zone | 55 |
healthcare facilities | 55 |
law enforcement | 55 |
crucial role | 55 |
genome replication | 55 |
study reported | 55 |
assay kit | 55 |
also detected | 55 |
molecular methods | 55 |
laboratory testing | 55 |
influenza pneumonia | 55 |
prediction model | 55 |
newly diagnosed | 55 |
luciferase reporter | 55 |
surveillance systems | 55 |
emerging pathogens | 55 |
study using | 55 |
bowel disease | 55 |
proposed model | 55 |
magnetic resonance | 55 |
growth rate | 55 |
human igg | 55 |
six patients | 55 |
zoonotic viruses | 55 |
dual practice | 55 |
medical university | 55 |
lung volume | 55 |
two main | 55 |
higher rates | 55 |
infect dis | 55 |
visual field | 55 |
epidemiological studies | 55 |
cell migration | 55 |
heavy chain | 55 |
chronic infection | 55 |
randomised controlled | 54 |
plasmid dna | 54 |
results demonstrate | 54 |
evolutionary history | 54 |
randomized clinical | 54 |
blood vessels | 54 |
deficient cells | 54 |
many years | 54 |
two distinct | 54 |
anterior resection | 54 |
cell signaling | 54 |
haemorrhagic fever | 54 |
human infections | 54 |
organ transplantation | 54 |
data regarding | 54 |
various types | 54 |
current status | 54 |
tissue engineering | 54 |
regression models | 54 |
ml min | 54 |
vitro studies | 54 |
serial dilutions | 54 |
ag cur | 54 |
salmonella enterica | 54 |
experimental studies | 54 |
healthcare settings | 54 |
multiplex real | 54 |
risk communication | 54 |
falciparum malaria | 54 |
health workers | 54 |
coding region | 54 |
tyrosine kinase | 54 |
host proteins | 54 |
immune dysregulation | 54 |
epithelial cell | 54 |
flow rate | 54 |
invasive approach | 54 |
total gastrectomy | 54 |
effective treatment | 54 |
aedes aegypti | 54 |
light chain | 54 |
situ hybridization | 54 |
hydrogen peroxide | 54 |
human cytomegalovirus | 54 |
adjuvanted wiv | 54 |
collected data | 54 |
subunit vaccine | 54 |
liquid chromatography | 54 |
financial support | 54 |
mrna delivery | 54 |
fl mice | 53 |
early onset | 53 |
viral hepatitis | 53 |
mathematical model | 53 |
oral cavity | 53 |
first year | 53 |
pathogen detection | 53 |
renal transplantation | 53 |
quantified using | 53 |
source localization | 53 |
complex networks | 53 |
brain barrier | 53 |
based assay | 53 |
enzymatic activity | 53 |
increased expression | 53 |
false positive | 53 |
confocal microscopy | 53 |
based methods | 53 |
like protease | 53 |
poorly understood | 53 |
cells per | 53 |
retrospectively reviewed | 53 |
intravascular coagulation | 53 |
emergency room | 53 |
obtained using | 53 |
data showed | 53 |
compared using | 53 |
cystic duct | 53 |
different viruses | 53 |
host disease | 53 |
hemolytic anemia | 53 |
studies suggest | 53 |
consecutive patients | 53 |
new world | 53 |
preserved eggs | 53 |
novel human | 53 |
encephalomyelitis virus | 53 |
cultured cells | 53 |
cell function | 53 |
stimulated genes | 53 |
ebola epidemic | 53 |
relative space | 53 |
pig traders | 53 |
mask use | 53 |
mice immunized | 53 |
sequence similarity | 53 |
hpv types | 52 |
natural infection | 52 |
inactivated vaccine | 52 |
technological convergence | 52 |
specific primers | 52 |
elderly patients | 52 |
operating room | 52 |
stop codon | 52 |
based assays | 52 |
treated patients | 52 |
medical record | 52 |
acid residues | 52 |
prognostic factors | 52 |
results demonstrated | 52 |
pfu ml | 52 |
times higher | 52 |
olfactory bulb | 52 |
family history | 52 |
plasma cells | 52 |
study included | 52 |
boundary layer | 52 |
predictive value | 52 |
dna extraction | 52 |
speaking researchers | 52 |
indoor air | 52 |
may represent | 52 |
pcr testing | 52 |
respiratory samples | 52 |
common respiratory | 52 |
virus vaccines | 52 |
circovirus type | 52 |
sectional study | 52 |
included studies | 52 |
animal experiments | 52 |
previous work | 52 |
patients diagnosed | 52 |
electronic supplementary | 52 |
genes encoding | 52 |
respiratory signs | 52 |
complement activation | 52 |
mammalian cell | 52 |
related complications | 52 |
mediated immune | 52 |
using two | 52 |
mm hepes | 52 |
may increase | 52 |
conformational changes | 52 |
influenza surveillance | 52 |
pulmonary tuberculosis | 51 |
available data | 51 |
molecular diagnostic | 51 |
maximum likelihood | 51 |
using graphpad | 51 |
attenuated vaccines | 51 |
hours post | 51 |
host evolution | 51 |
expression vector | 51 |
high affinity | 51 |
th century | 51 |
adenovirus infection | 51 |
inhibitory effects | 51 |
causative agents | 51 |
rapid diagnostic | 51 |
hbv replication | 51 |
identified using | 51 |
electronic medical | 51 |
molecular basis | 51 |
patients hospitalized | 51 |
single center | 51 |
mucosal immunity | 51 |
operating time | 51 |
healthy adults | 51 |
risk patients | 51 |
genome editing | 51 |
year period | 51 |
arabian peninsula | 51 |
dna levels | 51 |
animals infected | 51 |
emergency management | 51 |
use committee | 51 |
oxidative damage | 51 |
fuzzy logic | 51 |
showed significant | 51 |
science foundation | 51 |
increased levels | 51 |
human body | 51 |
heart rate | 51 |
tertiary care | 51 |
protein sequences | 51 |
optical density | 51 |
univariate analysis | 51 |
dna sequences | 51 |
major cause | 51 |
lower levels | 50 |
square test | 50 |
mm edta | 50 |
preterm infants | 50 |
microglial cells | 50 |
six months | 50 |
acute lower | 50 |
substance misuse | 50 |
outbreak size | 50 |
resistant bacteria | 50 |
disease emergence | 50 |
incisional hernia | 50 |
positive controls | 50 |
relative relationship | 50 |
antigen detection | 50 |
antiviral innate | 50 |
slightly higher | 50 |
private sector | 50 |
median follow | 50 |
investigate whether | 50 |
cell subsets | 50 |
pcr system | 50 |
independent risk | 50 |
genomic sequences | 50 |
simulation results | 50 |
nonhuman primates | 50 |
one month | 50 |
population size | 50 |
forming units | 50 |
corticosteroid treatment | 50 |
veterinary medicine | 50 |
igg antibody | 50 |
human bocavirus | 50 |
least three | 50 |
liver resection | 50 |
hib crude | 50 |
done using | 50 |
myeloid leukemia | 50 |
final manuscript | 50 |
significant impact | 50 |
chinese government | 50 |
persistent infection | 50 |
diseases society | 50 |
rhinovirus infection | 50 |
higher rate | 50 |
receptor signaling | 50 |
pediatric population | 50 |
immune activation | 50 |
based approach | 50 |
environmental conditions | 50 |
ebov infection | 50 |
study provides | 49 |
every year | 49 |
rna extraction | 49 |
state council | 49 |
inflammatory diseases | 49 |
per group | 49 |
clinical deterioration | 49 |
late preterm | 49 |
recombinant baculovirus | 49 |
increasing number | 49 |
treatment option | 49 |
health sector | 49 |
tumor microenvironment | 49 |
protein sequence | 49 |
mean operative | 49 |
indoor environments | 49 |
high quality | 49 |
inducible gene | 49 |
copy numbers | 49 |
major role | 49 |
otitis media | 49 |
term follow | 49 |
months post | 49 |
immune suppression | 49 |
comparative study | 49 |
bl mice | 49 |
salmonella dublin | 49 |
female patient | 49 |
significant effect | 49 |
much lower | 49 |
heat shock | 49 |
older age | 49 |
baseline characteristics | 49 |
one day | 49 |
systemic inflammation | 49 |
multiple sequence | 49 |
contains supplementary | 49 |
coronavirus hku | 49 |
smn copies | 49 |
mini kit | 49 |
protein level | 49 |
delivery system | 49 |
viral mrna | 49 |
patients developed | 49 |
airway caliber | 49 |
success rate | 49 |
antiphospholipid syndrome | 49 |
rna genome | 49 |
health facilities | 49 |
nlrp inflammasome | 49 |
reporter gene | 49 |
surface antigen | 49 |
ards patients | 48 |
molecular docking | 48 |
polyclonal antibody | 48 |
marrow transplantation | 48 |
related diseases | 48 |
biological processes | 48 |
catalytic activity | 48 |
first two | 48 |
patient characteristics | 48 |
discharged home | 48 |
airway wall | 48 |
high degree | 48 |
health outcomes | 48 |
natural history | 48 |
femoral head | 48 |
autosomal recessive | 48 |
may serve | 48 |
mutation rate | 48 |
asm strain | 48 |
highly contagious | 48 |
significant risk | 48 |
cardiac arrest | 48 |
antibacterial activity | 48 |
index case | 48 |
might also | 48 |
vivo studies | 48 |
carbon dioxide | 48 |
north american | 48 |
tumor cell | 48 |
highly effective | 48 |
pig farms | 48 |
serum igg | 48 |
may affect | 48 |
viral fusion | 48 |
also shown | 48 |
several factors | 48 |
weeks post | 48 |
also tested | 48 |
differences among | 48 |
vertical transmission | 48 |
control mice | 48 |
high morbidity | 48 |
chronic lung | 48 |
papn ectodomain | 48 |
host genetic | 48 |
european union | 48 |
bd biosciences | 48 |
average number | 48 |
viral pathogenesis | 48 |
health surveillance | 48 |
molecular evolutionary | 48 |
will provide | 48 |
dengue infection | 48 |
hajj pilgrims | 48 |
social support | 48 |
lupus erythematosus | 48 |
vp lc | 48 |
infected cats | 48 |
molecular patterns | 48 |
cell population | 48 |
ubiquitin chains | 48 |
large numbers | 48 |
school health | 48 |
chadox schikv | 48 |
treated cells | 48 |
humoral immunity | 47 |
inflammatory cells | 47 |
blood count | 47 |
social network | 47 |
level wind | 47 |
virus genomes | 47 |
ventilated patients | 47 |
rna silencing | 47 |
postoperative period | 47 |
cellular receptor | 47 |
target protein | 47 |
ubiquitin ligase | 47 |
significant association | 47 |
emergency response | 47 |
authorized users | 47 |
interferon production | 47 |
overlapping genes | 47 |
mouse igg | 47 |
molecular assays | 47 |
target cell | 47 |
obese patients | 47 |
surgical approach | 47 |
many cases | 47 |
interquartile range | 47 |
sybr green | 47 |
sequencing data | 47 |
antiviral signaling | 47 |
antioxidant activity | 47 |
new technologies | 47 |
clinical severity | 47 |
bei der | 47 |
available online | 47 |
target gene | 47 |
inflammatory markers | 47 |
llama serum | 47 |
feline immunodeficiency | 47 |
hygiene practice | 47 |
gold nanoparticle | 47 |
emerging risks | 47 |
en el | 47 |
lessons learned | 47 |
see supplementary | 47 |
i ifns | 47 |
genetic material | 47 |
future work | 47 |
international health | 47 |
systemic lupus | 47 |
genomic rna | 47 |
cervical cancer | 47 |
age years | 47 |
supplementary data | 47 |
general procedure | 47 |
also performed | 47 |
economic hardship | 47 |
surgical outcomes | 47 |
rabbit igg | 47 |
corresponding author | 47 |
malaria vaccine | 47 |
bat coronavirus | 47 |
retinoic acid | 47 |
enteric pathogens | 46 |
virus hemagglutinin | 46 |
different regions | 46 |
tumor size | 46 |
cancer cachexia | 46 |
medium containing | 46 |
seven patients | 46 |
birth weight | 46 |
recombinant vaccinia | 46 |
hygiene compliance | 46 |
animal studies | 46 |
arbaeen ceremony | 46 |
viruses isolated | 46 |
diagnostic tool | 46 |
genetic testing | 46 |
seven days | 46 |
therapeutic targets | 46 |
chb patients | 46 |
link prediction | 46 |
upper gi | 46 |
neutrophil count | 46 |
emerging viruses | 46 |
natural product | 46 |
extracellular vesicles | 46 |
jak stat | 46 |
care facilities | 46 |
urgent need | 46 |
institutional animal | 46 |
also important | 46 |
potential therapeutic | 46 |
viral life | 46 |
childhood cancer | 46 |
close proximity | 46 |
point mutations | 46 |
risk management | 46 |
ibv infection | 46 |
virus antigen | 46 |
infectious agent | 46 |
growth kinetics | 46 |
zoonotic disease | 46 |
constructed using | 46 |
information regarding | 46 |
protein complexes | 46 |
vaccine safety | 46 |
death rate | 46 |
plasmacytoid dendritic | 46 |
large scale | 46 |
operative day | 46 |
healthy individuals | 46 |
lung function | 46 |
specific immune | 46 |
sendai virus | 46 |
stimulating factor | 46 |
i ku | 46 |
celiac disease | 46 |
serum creatinine | 46 |
nucleoside analogs | 46 |
ischemic stroke | 46 |
virus glycoprotein | 46 |
type iii | 45 |
extracellular matrix | 45 |
renal replacement | 45 |
green tea | 45 |
tb patients | 45 |
two months | 45 |
first study | 45 |
uninfected cells | 45 |
study revealed | 45 |
hpv psv | 45 |
fluorescence imaging | 45 |
network structure | 45 |
mainland china | 45 |
infectious remains | 45 |
using spss | 45 |
luciferase activity | 45 |
molecular mechanism | 45 |
diagnostic laparoscopy | 45 |
influenza epidemics | 45 |
central role | 45 |
ml penicillin | 45 |
lymphoid tissue | 45 |
antiviral immune | 45 |
thoracic society | 45 |
equine encephalitis | 45 |
limited number | 45 |
different species | 45 |
acute appendicitis | 45 |
drinking water | 45 |
expression profiles | 45 |
transmembrane domain | 45 |
messenger rna | 45 |
may require | 45 |
intestinal epithelial | 45 |
cellular proteins | 45 |
randomly selected | 45 |
traditional chinese | 45 |
assay using | 45 |
case patients | 45 |
ion channel | 45 |
macrophage activation | 45 |
single nucleotide | 45 |
one another | 45 |
table shows | 45 |
avian coronavirus | 45 |
silica gel | 45 |
different groups | 45 |
soft tissue | 45 |
one hand | 45 |
single dose | 45 |
activated protein | 45 |
zoonotic pathogens | 45 |
different concentrations | 45 |
severe malaria | 45 |
may include | 45 |
high throughput | 45 |
ffi ffi | 45 |
protease inhibitor | 45 |
first months | 45 |
human genome | 45 |
mgfapcre ifnar | 45 |
live virus | 45 |
listeria monocytogenes | 45 |
infections caused | 45 |
research center | 45 |
biofilm formation | 45 |
virus titer | 45 |
trauma patients | 45 |
chemical composition | 45 |
see footnote | 45 |
supplementary materials | 45 |
potential risk | 45 |
dna sequence | 45 |
human cases | 45 |
highly expressed | 45 |
internal hernia | 44 |
immunofluorescence assay | 44 |
oncology patients | 44 |
virus outbreak | 44 |
bars represent | 44 |
health professionals | 44 |
global fund | 44 |
patient demographics | 44 |
well established | 44 |
viral envelope | 44 |
exclusion criteria | 44 |
hospital length | 44 |
domestic animals | 44 |
related viruses | 44 |
near future | 44 |
naturally infected | 44 |
absolute space | 44 |
year follow | 44 |
field strains | 44 |
hcv rna | 44 |
health problems | 44 |
selective pressure | 44 |
fresh produce | 44 |
cancer surgery | 44 |
acute cholecystitis | 44 |
host innate | 44 |
brain tissue | 44 |
showed high | 44 |
adenovirus type | 44 |
replication cycle | 44 |
type atpases | 44 |
linear interpolation | 44 |
postoperative course | 44 |
protein degradation | 44 |
frequently detected | 44 |
significantly less | 44 |
acute myeloid | 44 |
bovine coronavirus | 44 |
autoimmune disease | 44 |
animal welfare | 44 |
primary antibody | 44 |
building density | 44 |
research institute | 44 |
murine model | 44 |
cell adhesion | 44 |
filamentous bacteria | 44 |
human diseases | 44 |
among hospitalized | 44 |
using anti | 44 |
node i | 44 |
rural areas | 44 |
prism software | 44 |
turnaround time | 44 |
published data | 44 |
clinical research | 44 |
male patient | 44 |
deficient mice | 44 |
peptide vaccine | 44 |
allowed us | 44 |
increased susceptibility | 44 |
primary human | 44 |
current knowledge | 43 |
treatment strategies | 43 |
vaccine evolution | 43 |
cohort studies | 43 |
single institution | 43 |
medical treatment | 43 |
cx cr | 43 |
severe sepsis | 43 |
south african | 43 |
will require | 43 |
recombinant human | 43 |
eukaryotic cells | 43 |
distilled water | 43 |
two studies | 43 |
target proteins | 43 |
severe cap | 43 |
potential conflicts | 43 |
also associated | 43 |
developed countries | 43 |
portal vertex | 43 |
entry inhibitors | 43 |
nosocomial transmission | 43 |
first days | 43 |
positive correlation | 43 |
coding sequences | 43 |
will allow | 43 |
cardiovascular disease | 43 |
distal gastrectomy | 43 |
among healthcare | 43 |
marrow transplant | 43 |
quantitative analysis | 43 |
first line | 43 |
cd receptors | 43 |
cell fusion | 43 |
experimental conditions | 43 |
disease spread | 43 |
bile acids | 43 |
pandemic preparedness | 43 |
important roles | 43 |
complement system | 43 |
negative results | 43 |
clinical evaluation | 43 |
total score | 43 |
chemokine receptor | 43 |
air quality | 43 |
pue case | 43 |
assessment tool | 43 |
inflammatory mediators | 43 |
previous research | 43 |
studies revealed | 43 |
negatively charged | 43 |
sexually transmitted | 43 |
medical care | 43 |
healthy children | 43 |
pulmonary function | 43 |
malaria parasite | 43 |
protective effects | 43 |
viral nucleic | 43 |
technical assistance | 43 |
blfp crude | 43 |
short term | 43 |
mg day | 43 |
molecular evolution | 43 |
written informed | 43 |
cek cells | 43 |
cell lung | 43 |
independently associated | 43 |
differential expression | 43 |
fusion peptide | 43 |
dna sequencing | 43 |
seq data | 43 |
outcome measures | 43 |
parameter values | 43 |
laparoscopic repair | 42 |
sequence identity | 42 |
transmission electron | 42 |
cleavage activity | 42 |
human primates | 42 |
elisa kit | 42 |
large amount | 42 |
passive immunization | 42 |
cellular mrnas | 42 |
pediatric hematology | 42 |
ring vaccination | 42 |
information system | 42 |
last decade | 42 |
thrombotic thrombocytopenic | 42 |
web server | 42 |
mycoplasma pneumoniae | 42 |
new cases | 42 |
will continue | 42 |
cytoplasmic tail | 42 |
gn pigs | 42 |
correlation analysis | 42 |
requiring hospitalization | 42 |
antimicrobial stewardship | 42 |
suspected cases | 42 |
throat swabs | 42 |
post operative | 42 |
viral strains | 42 |
economic development | 42 |
evolutionary genetics | 42 |
mers patients | 42 |
washed twice | 42 |
flash chromatography | 42 |
among others | 42 |
segmented filamentous | 42 |
expressed genes | 42 |
virus challenge | 42 |
graphpad software | 42 |
qualitative research | 42 |
found online | 42 |
mutant virus | 42 |
coronary artery | 42 |
neonatal piglets | 42 |
transforming growth | 42 |
factors influencing | 42 |
severe cases | 42 |
vaccine design | 42 |
reverse phase | 42 |
practice research | 42 |
rapid response | 42 |
cells may | 42 |
liver injury | 42 |
zikv strains | 42 |
coronavirus replication | 42 |
false discovery | 42 |
molecule inhibitors | 42 |
safety profile | 42 |
therapeutic target | 42 |
economic impact | 42 |
cell epitope | 42 |
will likely | 42 |
broadly neutralizing | 42 |
virus isolates | 41 |
susceptible population | 41 |
adaptor protein | 41 |
th day | 41 |
functional characterization | 41 |
adjuvant chemotherapy | 41 |
human coronaviruses | 41 |
chronic pain | 41 |
positive rate | 41 |
using real | 41 |
nuclear localization | 41 |
parainfluenza viruses | 41 |
general anesthesia | 41 |
urban areas | 41 |
hpv infection | 41 |
drug resistant | 41 |
high viral | 41 |
respiratory specimens | 41 |
interferon response | 41 |
different mechanisms | 41 |
ms analysis | 41 |
scale bar | 41 |
international committee | 41 |
higher level | 41 |
hydrogen bond | 41 |
respiratory illnesses | 41 |
wind speeds | 41 |
mathematical models | 41 |
disease caused | 41 |
graphene oxide | 41 |
cytomegalovirus infection | 41 |
total protein | 41 |
puerto rico | 41 |
selected patients | 41 |
subunit vaccines | 41 |
longitudinal study | 41 |
serum levels | 41 |
disaster medicine | 41 |
infected population | 41 |
mortality among | 41 |
dna level | 41 |
within normal | 41 |
three years | 41 |
cellular immunity | 41 |
significant morbidity | 41 |
neuropathic pain | 41 |
empty vector | 41 |
significant improvement | 41 |
huh cells | 41 |
highly virulent | 41 |
sputum samples | 41 |
small sample | 41 |
twisted wind | 41 |
state university | 41 |
associated molecular | 41 |
experimental study | 41 |
alkaline phosphatase | 41 |
conventional rt | 41 |
will lead | 41 |
using standard | 41 |
detection method | 41 |
medical research | 41 |
factors affecting | 41 |
venezuelan equine | 41 |
irrigation water | 41 |
total mesorectal | 41 |
also present | 41 |
infections due | 41 |
molecular techniques | 41 |
pedv rna | 41 |
viruses doi | 41 |
forest virus | 41 |
quantitative real | 41 |
well documented | 41 |
sting pathway | 40 |
hernia repairs | 40 |
glycosylation sites | 40 |
also play | 40 |
resonance imaging | 40 |
relative humidity | 40 |
study aims | 40 |
high specificity | 40 |
relative abundance | 40 |
secondary cases | 40 |
healthcare system | 40 |
fluorescence intensity | 40 |
software version | 40 |
thrombotic microangiopathy | 40 |
days prior | 40 |
low dose | 40 |
treatment failure | 40 |
positive blood | 40 |
occupational health | 40 |
rhesus macaque | 40 |
fluorescent protein | 40 |
type virus | 40 |
viral antigen | 40 |
epidermal growth | 40 |
laboratory animals | 40 |
ml kg | 40 |
first week | 40 |
immune reconstitution | 40 |
cell infiltration | 40 |
human hepatitis | 40 |
previously shown | 40 |
complication rates | 40 |
swab samples | 40 |
green fluorescent | 40 |
envelope features | 40 |
cytokine levels | 40 |
assisted surgery | 40 |
operative complications | 40 |
gastroesophageal reflux | 40 |
comparative analysis | 40 |
early phase | 40 |
postoperative hospital | 40 |
st century | 40 |
five years | 40 |
cell therapy | 40 |
antimicrobial therapy | 40 |
endothelial cell | 40 |
simple method | 40 |
lassa fever | 40 |
surface protein | 40 |
give compound | 40 |
clinical settings | 40 |
may explain | 40 |
first isolated | 40 |
endemic areas | 40 |
note springer | 40 |
acid composition | 40 |
management research | 40 |
dna repair | 40 |
high rates | 40 |
virus taxonomy | 40 |
acute viral | 40 |
conventional method | 40 |
gene transfer | 40 |
influenza infections | 40 |
culture media | 40 |
immune signaling | 40 |
gene encoding | 40 |
chronic liver | 40 |
virus neutralization | 40 |
antiviral effects | 40 |
environmental contamination | 40 |
study demonstrates | 40 |
viruses associated | 40 |
vascular endothelial | 40 |
positive bacteria | 40 |
reservoir hosts | 40 |
mesorectal excision | 40 |
common bile | 40 |
mortality associated | 40 |
coding rnas | 40 |
hospital admissions | 40 |
several limitations | 40 |
viral vectors | 40 |
three major | 40 |
viruses may | 40 |
network analysis | 40 |
different countries | 40 |
hemophagocytic lymphohistiocytosis | 40 |
three types | 40 |
meo ma | 40 |
different age | 40 |
community acquired | 40 |
see methods | 40 |
cell invasion | 39 |
single port | 39 |
primary immune | 39 |
selection pressure | 39 |
challenged birds | 39 |
teaching hospital | 39 |
shock protein | 39 |
mouse strains | 39 |
cfd simulation | 39 |
new approach | 39 |
randomized trial | 39 |
infectious dose | 39 |
primate cd | 39 |
filmarray respiratory | 39 |
study designs | 39 |
vaccination status | 39 |
lipid droplets | 39 |
proteasomal degradation | 39 |
also contribute | 39 |
ifn expression | 39 |
complete protection | 39 |
chinese medicine | 39 |
terminal region | 39 |
associated herpesvirus | 39 |
cytopathic effect | 39 |
binding rate | 39 |
factor alpha | 39 |
tissue tropism | 39 |
sialic acids | 39 |
onset preeclampsia | 39 |
information products | 39 |
recurrent infections | 39 |
large proportion | 39 |
many viruses | 39 |
cdna clone | 39 |
mf prevalence | 39 |
years later | 39 |
civil society | 39 |
mobile phone | 39 |
splenic flexure | 39 |
nasal discharge | 39 |
identify patients | 39 |
icu mortality | 39 |
noncoding rna | 39 |
wind comfort | 39 |
mass spectrometer | 39 |
cell receptors | 39 |
virus using | 39 |
drug repurposing | 39 |
binding activity | 39 |
cov cases | 39 |
piglets born | 39 |
systematic reviews | 39 |
months later | 39 |
experimental design | 39 |
phenolic compounds | 39 |
low pathogenic | 39 |
ml streptomycin | 39 |